Sermorelin

FDA Approved

Sermorelin (GRF 1-29)

Category
Growth Hormone
Aliases
GRF 1-29, Geref
Administration
Subcutaneous injection

Research and regulatory

Development stage

Previously FDA approved (Geref, 1990s) for diagnosing growth hormone deficiency in children; the brand was discontinued by the manufacturer for commercial reasons, not safety.

Legal and regulatory

Formerly FDA-approved product (Geref), now discontinued; compounded sermorelin is available via prescription through compounding pharmacies.

Side effects

Injection site redness, flushing, headache; generally well-tolerated